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ABSTRACT 
 
Objective: Visual hallucinations are common in dementia with Lewy bodies (DLB), although their 
etiology is unclear. This study aimed to investigate the relationship between severity and frequency 
of hallucinations and regional brain glucose metabolism. 
Methods: We performed brain FDG-PET scanning on 28 subjects with DLB (mean age 76). The 
neuropsychiatric index (NPI) was used to assess frequency and severity of hallucinations. We used 
the SPM package to investigate voxelwise correlations between NPI hallucination score (severity x 
frequency) and FDG uptake relative to the cerebellum. 
Results: There was a bilateral medial occipital region where reduced FDG was associated with 
increased  hallucination severity and frequency.  
Conclusion: The reduced occipital metabolism frequently seen in DLB is associated with frequency 
and severity of visual hallucinations. Further studies are required to investigate whether this is the 
result of deficits in top-down or bottom-up visual processing pathways. 
  
 INTRODUCTION 
 
Visual hallucinations are a common and distressing feature in DLB, but their etiology is still unclear 
(Onofrj et al. 2013). Although reduced occipital and parietal perfusion, and glucose metabolism, are 
well documented in DLB compared to healthy subjects, (Colloby et al. 2002; Ishii et al. 1999; O'Brien 
et al. 2014) few studies have investigated the relationship with hallucinations within DLB subjects, 
and results have been mixed. We investigated the relationship between hallucinations as measured 
by the neuropsychiatric inventory, and FDG-PET brain imaging in a cohort of patients with DLB. We 
hypothesised that more severe hallucinations would be associated with reduced glucose metabolism 
in visual processing areas. 
 
METHODS 
Subjects 
Subjects were part of a study investigating the relative performance of FDG-PET vs perfusion SPECT 
in the diagnosis of AD and DLB. Main results from the study have been reported elsewhere (O'Brien 
et al. 2014). The study subjects were recruited prospectively from people aged over 60 with mild to 
moderate dementia (MMSE>12) referred to clinical services in North-East England.  In this report, we 
only examined the subjects who met criteria for probable DLB (McKeith et al. 2005). The study was 
approved by the local Ethics Committee, and all participants (or nominated Independent Mental 
Capacity Advocate where participant lacked capacity) gave informed consent before participating. 
Clinical diagnosis was made by consensus between 3 experienced clinicians. All subjects had to have 
sufficient command of English and adequate visual and auditory acuity to allow cognitive and 
neuropsychological testing. Exclusion criteria were a) past history of alcohol or drug dependence; b) 
contraindications for FDG-PET scanning (e.g. inability to lie flat); c) fasting blood glucose level > 180 
mg / dL.  We recruited 30 subjects with DLB who were successfully scanned with FDG-PET-CT.  
Subjects underwent detailed neuropsychiatric investigation including the Cambridge Cognitive 
Examination (CAMCOG).  Parkinsonian motor features were assessed in all subjects using the motor 
subsection of the Unified Parkinson’s Disease Rating Scale (UPDRS III). To assess hallucinations and 
other neuropsychiatric features occuring in the month before assessment, we performed the 
Neuropsychiatric inventory (NPI) (Cummings et al. 1994). The NPI was not done in one subject due to 
lack of a suitable informant, and this subject was excluded from the analysis. An additional subject 
was excluded as the reported hallucinations were of a non visual nature, leaving 28 in the analysis. 
 
Scanning 
FDG-PET head scans were done over 10 min using a Siemens Biograph Truepoint  FDG-PET-CT 
starting 30 min after iv administration of 250 MBq F-18 FDG.  Siemens software was used for 
iterative reconstruction with scatter and attenuation correction based on the CT scan data obtained 
immediately before the FDG-PET scan. Patients were injected in quiet surroundings with minimal 
distractions and eyes open. 
SPM analysis 
As described in more detail elsewhere, (O'Brien et al. 2014) the PET scans were non-linearly spatially 
normalised to a study specific template. Scans were intensity normalised to the mean within a 
cerebellar region-of-interest (ROI) and smoothed with a 8mm Gaussian. SPM8 
(www.fil.ion.ucl.ac.uk/spm) was used to perform a voxelwise correlation between NPI hallucination 
score and normalised FDG intensity with additional covariates of CAMCOG, UPDRS III and disease 
duration. The statistic images were thresholded at p <0.001 voxelwise, and clusters taken to be 
significant at p < 0.05 FWE (familywise error) corrected for multiple comparisons. The SPM Anatomy 
toolbox was used to identify anatomic labels for significant clusters. 
RESULTS 
Table 1 shows the subject demographics. There were 8 subjects in whom hallucinations were not 
reported on the NPI, 11 with purely visual hallucinations, and 9 with visual plus auditory or tactile 
hallucinations. Supplementary table 1 shows the distribution of NPI frequency and severity scores. 
Figure 1 and supplementary table 2 show the results of the SPM analysis. There was a significant 
bilateral cluster which showed decreased FDG uptake with increasing NPI hallucination frequency x 
severity score in the occipital lobe, which was 51% in Area 17, 23% in Area 18, and 15% V3v. Analysis 
of the severity and frequency hallucination NPI scores separately produced very similar results, with 
both scores correlating with occipital hypometabolism (supplementary figure 1). There were no 
significant clusters elsewhere, nor any regions where increased FDG uptake correlated with 
increased NPI hallucination score. 
Table 1: Demographics on the 28 subjects included. 
 Mean (SD) 
Age 76.4 (6.0) 
Sex (F/M) 5/23 
Duration illness (months) 39.3 (27.9) 
CAMCOG 72.1 (13.4) 
MMSE score 21.7 (4.2) 
NPI_Halltot 2.43 (2.69) 
NPI Hallucination frequency 1.86 (1.58) 
NPI Hallucination severity 0.93 (0.81) 
UPDRS III  25.8 (11.8) 
 
DISCUSSION 
We found a significant relationship between hallucination severity and reduced glucose metabolism 
in the primary visual cortex of subjects with DLB.  
We are only aware of two studies which have directly investigated the relationship between occipital 
hypometabolism and hallucinations. Perneczky et al. (2008) found reduction in the occipito-
temporal region in those DLB with hallucinations vs. without, whilst Imamura et al. (1999) found 
reduced occipital metabolism in all DLB subjects, but those with hallucinations had relatively 
preserved posterior temporal and parietal metabolism compared to non-hallucinators. A small study 
of FDG in DLB (Okamura et al. 2001) found reduced uptake in the visual association cortex of the DLB 
group compared to the AD group irrespective of clinical severity of the disease. 
Using perfusion SPECT, a number of studies (Colloby et al. 2002; Ishii et al. 1999) report reduced 
occipital perfusion in DLB, but do not mention whether this correlated with hallucination severity. 
Pasquier et al. (2002) found lower perfusion of the occipital region in DLB with vs. without 
hallucinations, however, Lobotesis et al. (2001) found reduced occipital perfusion in DLB overall, but 
no difference between those with or without hallucinations.  
Possible explanations for the reduced occipital glucose metabolism include pathological changes to 
the occipital lobe itself, or disrupted top-down feedback from higher visual areas. Alterations to the 
cholinergic neurotransmitter system have been observed in the occipital lobe of DLB (Mukaetova-
Ladinska et al. 2013). 
Two studies have examined DLB patients with visual hallucinations before and after treatment with 
donepezil. These studies found that donepezil decreased the severity of hallucinations, but found 
conflicting imaging results, with one reporting occipital perfusion increased after treatment, (Mori et 
al. 2006) but the other decreased glucose metabolism (Satoh et al. 2010).  
A limitation of our study is that we did not record the presence of hallucinations during the scan, and 
the NPI refers to hallucinations during the preceding month. Hence our finding can only be related to 
a tendency for patients to hallucinate, rather than directly associated with hallucinations.  
One difference between our study and most previous ones, is that our scans were done with eyes 
open compared to eyes closed. The eyes open state is associated with increased occipital FDG 
uptake as well as increased functional connectivity between the occipital cortex and other brain 
regions (Riedl et al. 2014). Our results are therefore consistent with disrupted connectivity between 
the primary visual cortex and higher visual regions being associated with hallucinations. This is 
further supported by our previous finding that in an fMRI study of visual function the primary visual 
cortex activation was normal in DLB, whilst higher visual areas were abnormal, (Taylor et al. 2012) 
and a recent MRI study found correlation between NPI hallucination score and reduced cortical 
thickness in the superior parietal region of DLB.  
It is possible that differences in occipital FDG uptake between eyes open and eyes closed may reflect 
upon dysfunction in the bottom-up visual system, with those without hallucinations perhaps 
showing relatively increased uptake on eyes opening due to the increased input from the eye. This 
may account for differences between our study (eyes open, and hallucinators showing reduced 
occipital FDG) and that of Imamura et al. (1999) (eyes closed, no occipital difference with 
hallucination). However, further studies are needed to clarify the relationship between low medial 
occipital metabolism and hallucinations. 
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FIGURES 
Figure 1 Significant (voxelwise p <0.001 [t>3.4]) clusters for correlation of NPI-hallucination score 
(severity x frequency) and FDG uptake (normalised to cerebellum) , with additional covariates of 
UPDRS, disease duration and CAMCOG. Results overlaid on mean FDG-PET scan of participants. Scale 
shows T statistic. Crosshair on the significant left occipital cluster. 
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